Intellia Broadens Its Oncology Bets With CRISPR-Edited NK Cell Therapies
Partners ONK Therapeutics To Develop Five Candidates
Executive Summary
Intellia continues to expand across immuno-oncology, adding the promise of natural killer cells to its pipeline.
You may also be interested in...
Intellia Flags In Vivo CRISPR Knockout Platform As Key Priority For 2023
After ending 2022 with more than $1bn in cash, the US firm is keen to validate its in vivo approach to gene therapy with investigational new drug applications and pivotal trials lined up for two core rare disease programs.
Deal Watch: AbbVie Adds Neuroscience Heft With Syndesi Acquisition
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
Intellia Achieves Gene-Editing Breakthrough With First In Vivo CRISPR Therapy
The first use of CRISPR/Cas9 in humans shows promising safety and efficacy against rare disease ATTR, and opens up the possibility of treating many genetic diseases.